Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | CCR5 | P51681 | 4/20 | 0.49 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 2/20 | 0.46 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16431785 | 0.93 | EPHX2 (0.56) | TACR1OPRD1OPRK1CCR5DGAT2 | |
| SCHEMBL19226428 | 0.92 | TACR1 (0.60) | TACR1OPRD1OPRK1CCR5TSHR | |
| SCHEMBL24392451 | 0.90 | TACR1 (0.48) | TACR1OPRD1OPRK1CCR5TSHR | |
| SCHEMBL1206023 | 0.89 | TACR1 (0.53) | TACR1OPRD1OPRK1CCR5DGAT2 | |
| SCHEMBL31327719 | 0.88 | TACR1 (0.55) | TACR1OPRD1OPRK1CCR5DGAT2 | |
| SCHEMBL7000547 | 0.86 | TACR1 (0.54) | TACR1OPRD1OPRK1CCR5DGAT2 | |
| SCHEMBL3277361 | 0.85 | TACR1 (0.53) | TACR1OPRD1OPRK1CCR5DGAT2 | |
| SCHEMBL5621873 | 0.84 | TACR1 (0.53) | TACR1OPRD1OPRK1CCR5DGAT2 | |
| SCHEMBL17078067 | 0.84 | MEN1 (0.51) | TACR1OPRD1OPRK1CCR5EPHX2 | |
| SCHEMBL2270783 | 0.83 | TACR1 (0.61) | TACR1OPRD1OPRK1CCR5TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245014-B1 | UREA DERIVATIVES OF BENZOMORPHANES AND RELATED SCAFFOLDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INT (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-20110028445-A1 | Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028445-A1 | Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use | XDH, HSD11B1, HSD3B1 | TACR1 938/4885OPRD1 29/4885OPRK1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.